Bone News and Research

RSS

CMMC installs Toshiba's Vantage Titan MR system to accommodate bariatric patients

Obesity is a growing trend in the United States, requiring hospitals to provide medical imaging technology designed to accommodate bariatric patients without compromising diagnostic confidence or patient comfort. To accomplish this goal, Central Mississippi Medical Center in Jackson, Miss., a bariatric center of excellence, recently installed Toshiba America Medical Systems, Inc.'s Vantage Titan MR system.

28 Jun 2010

ADVANCE study provides new insights into the management of SHPT in CKD patients

Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism in chronic kidney disease patients. ADVANCE (A randomiseD VAscular calcificatioN study to evaluate the effects of CinacalcEt) is a randomised, controlled open label study to evaluate the effects of treatment with Mimpara (cinacalcet) plus low-dose vitamin D, compared to flexible doses of vitamin D alone, on the progression of vascular and valvular calcification in dialysis patients with SHPT.

28 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

EVISTA improves bone quality as measured by HRpQCT: IIT

Interim data from a prospective Investigator Initiated Trial presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by the high-resolution peripheral quantitative computed tomography.

28 Jun 2010

Medtronic introduces new Midas Rex Legend EHS Stylus Touch drill for spinal, cranial, orthopaedic procedures

Medtronic, Inc. today announced availability of the company's new Midas Rex® Legend® EHS Stylus Touch™ high-speed electric drill for spinal, cranial and orthopaedic surgical procedures. This is the first electric drill from Medtronic with integrated finger control and is based on the well-established Legend EHS Stylus® motor.

28 Jun 2010

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the marketing authorisation for VPRIV (velaglucerase alfa), the company's enzyme replacement therapy for the treatment of type 1 Gaucher disease.

28 Jun 2010

Athersys, CSCRM and CWRU receive $1M to advance MultiStem therapy for SCI

Athersys, Inc. and its collaborators, including the Center for Stem Cell and Regenerative Medicine and Case Western Reserve University, announced today that they have been awarded $1 million through the Ohio Third Frontier Biomedical Program to support research into the treatment of spinal cord injury with MultiStem, Athersys' proprietary stem cell product candidate.

25 Jun 2010

Japan's MHLW grants full marketing authorization to REVLIMID

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare for use in combination with dexamethasone as a treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy. This marketing authorization represents the first regulatory approval of REVLIMID in Japan.

25 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

Corgenix Medical issued additional U.S. patent covering AspirinWorks technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks technology and product line.

25 Jun 2010

$Repetitive impact on feet can increase risk of stress fractures$

Repetitive impact on feet can increase risk of stress fractures

Stress fractures of the foot are becoming more common in runners, especially first-time marathoners, according to the American College of Foot and Ankle Surgeons.

25 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

UNC team provides first example of successful radiomitigation in mammals

While radiation has therapeutic uses, too much radiation is damaging to cells. The most important acute side effect of radiation poisoning is damage to the bone marrow. The bone marrow produces all the normal blood cells, and therefore a high dose of radiation can lead to low blood counts of red cells, platelets and white blood cells.

24 Jun 2010

FDA grants t2cure orphan drug designation for t2c001 in Buerger's Disease

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of Buerger's Disease. The Company also announced that in a concurrent application in Europe the EMA's Committee for Orphan Medicinal Products recently recommended t2c001 for orphan designation to the European Commission.

24 Jun 2010

June issue of Clinic Women's HealthSource provides overview of anemia

Anemia is not a normal part of aging, yet it's fairly common in older adults and causes frailness, weakness and increased risk of falls. According to Mayo Clinic Women's HealthSource, more than one in 10 older adults has anemia. Twenty percent of women are anemic by age 85.

24 Jun 2010

US District Court grants injunction in favor of Smith & Nephew's Endoscopy Division

A US District Court judge in Texas yesterday ruled that it granted an injunction in favor of Smith & Nephew's Endoscopy Division. As expected the Judge also granted Arthrex's motion to stay the injunction pending an appeal of the judgment.

24 Jun 2010

Ingredients for an "anti-aging potion"

Aging without getting old? It's largely possible, according to the June issue of Mayo Clinic Health Letter.

24 Jun 2010

Spanish scientists propose human amniotic membrane as new tool for repairing damaged articular cartilage

Spanish scientists have proposed using human amniotic membrane as a new tool for repairing damaged human articular cartilage, which heals very poorly because of its low capacity for self-repair. Their research, published in the journal Cell and Tissue Banking, shows that the cellular density of the cartilage synthesised could be greater than that of the body's own natural cartilage.

23 Jun 2010